A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Experimental Neurology

• Publication date

  2009-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.expneurol.2009.03.004PMID 19289118
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments

  2008cited by this paper
• Identification and Allele-Specific Silencing of the Mutant Huntingtin Allele in Huntington's Disease Patient-Derived Fibroblasts

  2008cited by this paper
• Linking SNPs to CAG repeat length in Huntington's disease patients

  2008cited by this paper
• Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits

  2007cited by this paper
• Huntington's disease

  2007cited by this paper
• Target selectivity in mRNA silencing

  2006cited by this paper
• Designing siRNA That Distinguish between Genes That Differ by a Single Nucleotide

  2006cited by this paper
• rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse.

  2006cited by this paper
• Normal huntingtin function: an alternative approach to Huntington's disease

  2005cited by this paper
• RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

  2005cited by this paper
• Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.

  2005cited by this paper
• Huntingtin and the molecular pathogenesis of Huntington's disease

  2004cited by this paper
• Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules.

  2004cited by this paper
• Cortical and striatal neurone number in Huntington's disease

  2004cited by this paper
• Allele-specific silencing of dominant disease genes

  2003cited by this paper
• Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference.

  2002cited by this paper
• siRNA-mediated gene silencing in vitro and in vivo

  2002cited by this paper
• Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders.

  2002cited by this paper
• Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways

  2002cited by this paper
• Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease

  2001cited by this paper
• Wild-Type Huntingtin Protects from Apoptosis Upstream of Caspase-3

  2000cited by this paper
• Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice

  2000cited by this paper
• Identification of an HD patient with a (CAG)180 repeat expansion and the propagation of highly expanded CAG repeats in lambda phage

  1997cited by this paper
• Errors in Huntington disease diagnostic test caused by trinucleotide deletion in the IT15 gene.

  1996cited by this paper
• Inactivation of the mouse Huntington's disease gene homolog Hdh.

  1995cited by this paper
• Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population.

  1995cited by this paper
• Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue

  1995cited by this paper
• Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes.

  1995cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• Trinucleotide repeat length instability and age of onset in Huntington's disease

  1993cited by this paper

• Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines

  2025cites this paper
• The future of siRNA-mediated approaches to treat von Willebrand disease

  2025cites this paper
• Overview of Huntington’s Disease and Emerging Treatment Strategies: A Narrative Review

  2025cites this paper
• Double strand breaks drive toxicity in Huntington’s disease mice with or without somatic expansion

  2025cites this paper
• An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment.

  2024cites this paper
• DNA double-strand break-free CRISPR interference delays Huntington’s disease progression in mice

  2023cites this paper
• RNA antisense and silencing strategies using synthetic drugs for rare muscular and neuromuscular diseases

  2023cites this paper
• Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in vivo in CNS

  2022cites this paper
• Haplotype-specific insertion-deletion variations for allele-specific targeting in Huntington's disease

  2022cites this paper
• SUPT4H1-edited stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington’s disease

  2022cites this paper
• Allele-specific silencing as therapy for familial amyotrophic lateral sclerosis caused by the p.G376D TARDBP mutation

  2022cites this paper
• Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington’s disease models

  2022cites this paper
• Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations

  2022cites this paper
• DNAzyme Cleavage of CAG Repeat RNA in Polyglutamine Diseases

  2021cites this paper
• New Avenues for the Treatment of Huntington’s Disease

  2021cites this paper
• Allele-Specific Knockdown of Mutant Huntingtin Protein via Editing at Coding Region Single Nucleotide Polymorphism Heterozygosities

  2021cites this paper
• Innovative Therapeutic Approaches for Huntington’s Disease: From Nucleic Acids to GPCR-Targeting Small Molecules

  2021cites this paper
• Investigational Assay for Haplotype Phasing of the Huntingtin Gene

  2020influential citation
• Recent Advances in the Treatment of Huntington’s Disease: Targeting DNA and RNA

  2020cites this paper
• Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities

  2020cites this paper
• Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease

  2020influential citation
• The effects of huntingtin-lowering: what do we know so far?

  2019cites this paper
• A Comprehensive Haplotype Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease.

  2019cites this paper
• Nonhuman Primate Models of Huntington's Disease and Their Application in Translational Research.

  2018cites this paper
• Supplemental Treatment for Huntington’s Disease with miR-132 that Is Deficient in Huntington’s Disease Brain

  2018cites this paper
• Searching for ancient balanced polymorphisms shared between Neanderthals and Modern Humans

  2018cites this paper
• Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.

  2018cites this paper
• Edinburgh Explorer Allele-Specific Knockdown of ALS-Associated Mutant TDP-43 in Neural Stem Cells Derived from Induced Pluripotent Stem Cells

  2018cites this paper
• The therapeutic potential of RNA regulation in neurological disorders

  2018cites this paper
• Antisense oligonucleotides: the next frontier for treatment of neurological disorders

  2018cites this paper
• AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease

  2017cites this paper
• Evaluation de différentes stratégies thérapeutiques antisens pour le traitement de la maladie de Huntington

  2017cites this paper
• From huntingtin gene to Huntington’s disease-altering strategies

  2017cites this paper
• ASPsiRNA: A Resource of ASP-siRNAs Having Therapeutic Potential for Human Genetic Disorders and Algorithm for Prediction of Their Inhibitory Efficacy

  2017cites this paper
• Haplotype-based stratification of Huntington's disease

  2017cites this paper
• Gene suppression approaches to neurodegeneration

  2017cites this paper
• Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics

  2017cites this paper
• The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain

  2017cites this paper
• Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing

  2017cites this paper
• Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.

  2016cites this paper
• Exploring the beneficial effects of cardiorespiratory fitness and exercise on cerebrovascular health in Huntington’s Disease: a cross-species approach

  2016cites this paper
• Antisense Oligonucleotide Tool in Therapy for Polyglutamine Neurodegenerative Disorders

  2016cites this paper
• Use of human stem cells in Huntington disease modeling and translational research.

  2016cites this paper
• Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease

  2016cites this paper
• Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfalls.

  2015cites this paper
• The epigenetics of aging and neurodegeneration.

  2015cites this paper
• DNA Repair Deficiency in Huntington's Disease Fibroblasts and Induced Pluripotent Stem Cells

  2015cites this paper
• Allele-selective suppression of mutant genes in polyglutamine diseases

  2015cites this paper
• [Gene silencing approaches for the treatment of Huntington's disease].

  2015cites this paper
• Region-specific interneuronal degeneration in the human cerebral cortex in Huntington’s disease correlates with symptomatology

  2015cites this paper
• Update on Huntington's disease: advances in care and emerging therapeutic options.

  2015cites this paper
• Delivering a disease-modifying treatment for Huntington's disease.

  2015cites this paper
• Moving toward a gene therapy for Huntington’s disease

  2015cites this paper
• Preventing Formation of Toxic N-Terminal Huntingtin Fragments Through Antisense Oligonucleotide-Mediated Protein Modification

  2014cites this paper
• Treatment of osteogenesis imperfecta in adults.

  2014cites this paper
• M04 Preventing Formation Of Toxic N-terminal Huntingtin Fragments Through Antisense Oligonucleotide-mediated Protein Modification

  2014cites this paper
• Personalized gene silencing therapeutics for Huntington disease

  2014cites this paper
• Allele-specific silencing of mutant Ataxin-7 in SCA7 patient-derived fibroblasts

  2014cites this paper
• Huntingtin‐lowering strategies in Huntington's disease: Antisense oligonucleotides, small RNAs, and gene editing

  2014cites this paper
• Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?

  2014cites this paper
• Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients

  2014cites this paper
• Oligonucleotide-based strategies to combat polyglutamine diseases

  2014cites this paper
• Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.

  2014cites this paper
• Current therapeutic advances in patients and experimental models of Huntington's disease.

  2014cites this paper
• Allele-Specific Knockdown of ALS-Associated Mutant TDP-43 in Neural Stem Cells Derived from Induced Pluripotent Stem Cells

  2014cites this paper
• Allele-Specific Silencing of Mutant Huntingtin in Rodent Brain and Human Stem Cells

  2014cites this paper
• Targets for future clinical trials in Huntington's disease: What's in the pipeline?

  2014cites this paper
• Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease

  2014cites this paper
• Novel siRNA delivery strategy: a new “strand” in CNS translational medicine?

  2013cites this paper
• Silencing Mutant Ataxin-3 Rescues Motor Deficits and Neuropathology in Machado-Joseph Disease Transgenic Mice

  2013cites this paper
• Surveying the Landscape of Huntington's Disease Mechanisms, Measurements, and Medicines

  2013cites this paper
• Epigenetic Mechanisms of Neurodegeneration in Huntington’s Disease

  2013cites this paper
• Antisense Therapy in Neurology

  2013cites this paper
• Delivery Systems and Local Administration Routes for Therapeutic siRNA

  2013cites this paper
• Small non-coding RNAs add complexity to the RNA pathogenic mechanisms in trinucleotide repeat expansion diseases

  2013cites this paper
• Allele Dependent Silencing of Collagen Type I Using Small Interfering RNAs Targeting 3'UTR Indels - a Novel Therapeutic Approach in Osteogenesis Imperfecta

  2013cites this paper
• Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS

  2013cites this paper
• Lentiviral Vector-Mediated RNA Silencing in the Central Nervous System

  2013cites this paper
• Neurodegeneration and Ageing: A Fatal Encounter

  2013cites this paper
• Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes

  2013cites this paper
• Self-assembling modified β-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease.

  2013cites this paper
• The role of goal-setting theory on Iranian EFL learners’ motivation and self-efficacy

  2013cites this paper
• Myeloid cell function in Huntington's disease

  2013cites this paper
• Allele dependent silencing of collagen type I using small interfering RNAs targeting 3[prime]UTR indels [ndash] a novel therapeutic approach in osteogenesis imperfecta

  2013cites this paper
• Genetic and Therapeutic Studies

  2013cites this paper
• RNA therapy for polyglutamine neurodegenerative diseases

  2012cites this paper
• 6 Machado-Joseph Disease / Spinocerebellar Ataxia Type 3

  2012cites this paper
• Therapeutic Silencing of Mutant Huntingtin by Targeting Single Nucleotide Polymorphisms: A Dissertation

  2012cites this paper
• Novel cell models for the study of spinocerebellar ataxia type 7 pathogenesis and therapy in a South African patient cohort

  2012influential citation
• Allele-selective inhibition of trinucleotide repeat genes.

  2012cites this paper
• Mass spectrometric identification of novel posttranslational modification sites in Huntingtin

  2012cites this paper
• An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

  2012cites this paper
• Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.

  2012cites this paper
• Emerging role of non-coding RNA in neural plasticity, cognitive function, and neuropsychiatric disorders

  2012cites this paper
• Machado-Joseph disease/spinocerebellar ataxia type 3.

  2012cites this paper
• Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum

  2012cites this paper
• Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway

  2012cites this paper
• Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin.

  2012cites this paper
• Ameliorating Huntington's Disease by Targeting Huntingtin mRNA

  2012cites this paper
• Widespread suppression of huntingtin with convection-enhanced delivery of siRNA.

  2012cites this paper